The therapeutic potential of novel phosphate binders

Pediatric Nephrology

Volumn 20, Issue 3 SPEC. ISS., 2005, Pages 389-392

  Querfeld, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Calcium; Lanthanum; Phosphate binders; Phosphorus; Sevelamer

Indexed keywords

ALUMINUM DERIVATIVE; ANTILIPEMIC AGENT; BICARBONATE; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; COLESTYRAMINE; FERRIC AMMONIUM CITRATE; FERRIC CHLORIDE; FERRIC CITRATE; FERRIC HYDROXIDE; FERRITIN; IRON; IRON DEXTRAN; IRON POLYMALTOSE; LANTHANUM; LANTHANUM CARBONATE; NICOTINAMIDE; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; VITAMIN D;

AGE; ANEMIA; BLOOD TOXICITY; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BRAIN DISEASE; CALCIFICATION; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CHEMICAL COMPOSITION; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; DIARRHEA; DIET THERAPY; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG INDICATION; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; DRUG USE; EXPERIENCE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; IRON BLOOD LEVEL; METABOLIC ACIDOSIS; MORTALITY; NEUROTOXICITY; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PREVALENCE; PRIORITY JOURNAL; REFERENCE VALUE; RENAL OSTEODYSTROPHY; REVIEW; RISK ASSESSMENT; RISK FACTOR;

CHILD; EPOXY COMPOUNDS; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; PHOSPHORUS METABOLISM DISORDERS; POLYAMINES; POLYETHYLENES;

EID: 14644440542     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-004-1679-6     Document Type: Review

References (28)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617 1:STN:280:DyaK1c7ovFKlsw%3D%3D
2. Block GA (2000) Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients. Clin Nephrol 54:318-324
3. Block GA, Port FK (2000) Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35:1226-1237
4. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, Balk E, Lau J, Levin A, Kausz AT, Eknoyan G, Levey AS (2003) National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: Evaluation, classification, and stratification. Pediatrics 111:1416-1421 12777562
5. Eknoyan G, Levin A, Levin N (2004) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1-S201
6. Rostand SG, Drueke TB (1999) Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56:383-392 10.1046/j.1523-1755.1999.00575.x
7. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100-105 10.1161/01.CIR.0000020222.63035.C0
8. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM (2001) Smooth muscle cell phenotypic transition associated with calcification: Upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 89:1147-1154
9. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX (2003) Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63:1003-1011 10.1046/j.1523-1755.2003.00820.x
10. Hsu CH (1997) Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 29:641-649
11. Portale AA, Booth BE, Halloran BP, Morris RC Jr (1984) Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73:1580-1589
12. Kuizon BD, Salusky I (2004) Renal osteodystrophy. In: Avner ED, Harmon WE, Niaudet P (eds) Pediatric nephrology. Lippincott Williams and Wilkins, Philadelphia, pp 1347-1373
13. Clark AG, Oner A, Ward G, Turner C, Rigden SP, Haxcock GB, Chantler C (1989) Safety and efficacy of calcium carbonate in children with chronic renal failure. Nephrol Dial Transplant 4:539-544
14. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483 10.1056/ NEJM200005183422003
15. Eifinger F, Wahn F, Querfeld U, Pollok M, Gevargez A, Kriener P, Gronemeyer D (2000) Coronary artery calcifications in children and young adults treated with renal replacement therapy. Nephrol Dial Transplant 15:1892-1894
16. Hergesell O, Ritz E (2002) Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrol Dial Transplant 17:14-17 10.1093/ndt/17.1.14
17. Hsu CH, Patel SR, Young EW (1999) New phosphate binding agents: Ferric compounds. J Am Soc Nephrol 10:1274-1280
18. Chang JM, Hwang SJ, Tsai JC, Chen HC, Guh JY, Lai YH (1999) Effect of ferric polymaltose complex as a phosphate binder in haemodialysis patients. Nephrol Dial Transplant 14:1045-1047 10.1093/ndt/14.4.1045
19. Hergesell O, Ritz E (1999) Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 14:863-867 10.1093/ndt/14.4.863
20. Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH (2002) An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: Ferric citrate. Nephrol Dial Transplant 17:265-270 10.1093/ndt/ 17.2.265
21. Basu A, Chakrabarty K, Chatterjee GC (1982) Neurotoxicity of lanthanum chloride in newborn chicks. Toxicol Lett 14:21-25 10.1016/ 0378-4274(82)90005-4
22. Joy MS, Finn WF (2003) Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42:96-107 10.1016/ S0272-6386(03)00554-7
23. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int [Suppl] S73-S78
24. Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, Slatopolsky E (2002) The effects of sevelamer hydrochloride and calcium carbonate on idney calcification in uremic rats. J Am Soc Nephrol 13:2299-2308
25. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E (2003) Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64:1653-1661 10.1046/j.1523-1755.2003.00284.x
26. Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252 10.1046/j.1523-1755.2002.00434.x
27. Pieper A-K, Haffner D, Müller-Hönger R, Hoppe B, Plank C, Offner G, Bonzel K-E, John U, Fründ S, Klaus G, Link A, Düker G, Querfeld U (2003) Sevelamer vs. calcium acetate in children with chronic renal failure (abstract). Pediatr Nephrol 18:C16
28. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, Ebihara I, Koide H (2004) Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65:1099-1104 10.1111/ j.1523-1755.2004.00482.x